Login / Signup

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells.

Xiangnan GuanRuozhen HuYoonha ChoiShyam SrivatsBarzin Y NabetJohn SilvaLisa McGinnisRobert HendricksKatherine NutschKarl L BantaEllen DuongAlexis DunklePatrick S ChangChia-Jung HanStephanie MittmanNandini MoldenPallavi DaggumatiWendy ConnollyMelissa Lynne JohnsonDelvys Rodriguez AbreuByoung Chul ChoAntoine ItalianoIgnacio Gil-BazoEnriqueta FelipIra MellmanSanjeev MariathasanDavid S ShamesRaymond MengEugene Y ChiangRobert J JohnstonNamrata S Patil
Published in: Nature (2024)
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone 1 . However, there remains little consensus on the mechanism(s) of response with this combination 2 . Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophages, monocytes and dendritic cells through Fcγ receptors (FcγR), in turn driving anti-tumour CD8 + T cells from an exhausted effector-like state to a more memory-like state. These results reveal a mechanism of action through which TIGIT checkpoint inhibitors can remodel immunosuppressive tumour microenvironments, and suggest that FcγR engagement is an important consideration in anti-TIGIT antibody development.
Keyphrases